QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
NASDAQ:GENE

Genetic Technologies - GENE Stock Forecast, Price & News

$1.68
+0.02 (+1.20%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.62
$1.79
50-Day Range
$1.13
$1.68
52-Week Range
$0.95
$3.58
Volume
325,993 shs
Average Volume
72,510 shs
Market Capitalization
$25.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GENE stock logo

About Genetic Technologies (NASDAQ:GENE) Stock

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Genetic Technologies Stock Performance

GENE Stock opened at $1.66 on Thursday. Genetic Technologies has a 52-week low of $0.95 and a 52-week high of $3.58. The company has a 50-day moving average of $1.35 and a two-hundred day moving average of $1.62.

Receive GENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

GENE Stock News Headlines

Genetic Technologies reports 9M results
US Patent Office Grants Patent for COVID-19 Risk Test
Applied Genetic Q2 2022 Earnings Preview
Genetic Technologies reports FQ2 cash flow results
Genetic Technologies Reports Q2 FY22 Cash Flow Results
See More Headlines
Receive GENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

GENE Company Calendar

Today
8/11/2022
Next Earnings (Estimated)
8/30/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GENE
Employees
18
Year Founded
1989

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$90,000.00
Book Value
$1.05 per share

Miscellaneous

Free Float
N/A
Market Cap
$25.86 million
Optionable
Optionable
Beta
2.06

Social Links


Key Executives

  • Mr. Simon Morriss
    Chief Exec. Officer
  • Mr. Michael Tonroe ACA (Age 55)
    B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD, CFO & Company Sec.
    Comp: $196.65k
  • Mr. Stanley Sack (Age 57)
    Chief Operating Officer
    Comp: $97.64k
  • Dr. Richard Allman Ph.D. (Age 62)
    Chief Scientific Officer
    Comp: $138.48k
  • Mr. Paul Keith Mathieson Viney B. Bus
    FCI, FCPA, FGIA, Consultant
  • Mr. Carl S. Stubbings BSc
    Chief Commercial Officer













GENE Stock - Frequently Asked Questions

How have GENE shares performed in 2022?

Genetic Technologies' stock was trading at $1.88 at the start of the year. Since then, GENE shares have decreased by 10.6% and is now trading at $1.68.
View the best growth stocks for 2022 here
.

When is Genetic Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 30th 2022.
View our GENE earnings forecast
.

What other stocks do shareholders of Genetic Technologies own?

What is Genetic Technologies' stock symbol?

Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE."

Who are Genetic Technologies' major shareholders?

Genetic Technologies' stock is owned by a number of retail and institutional investors. Top institutional investors include Group One Trading L.P. (0.00%).

How do I buy shares of Genetic Technologies?

Shares of GENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genetic Technologies' stock price today?

One share of GENE stock can currently be purchased for approximately $1.68.

How much money does Genetic Technologies make?

Genetic Technologies (NASDAQ:GENE) has a market capitalization of $25.86 million and generates $90,000.00 in revenue each year.

When was Genetic Technologies founded?

Genetic Technologies was founded in 1989.

How can I contact Genetic Technologies?

Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The official website for the company is www.gtgcorporate.com. The biotechnology company can be reached via phone at (138) 412-7000, via email at ir@gtgcorporate.com, or via fax at 011-61-3-8412-7040.

This page (NASDAQ:GENE) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.